• Increase font size
  • Default font size
  • Decrease font size
Information for citizens
Information for medical specialists
Information for companies
Home Announcements
Information for medical specialists

The PRAC started a review of medicines containing factor VIII to evaluate the risk of developing inhibitor proteins in patients starting treatment for haemophilia A. This follows the recent publication of a study whose authors suggested that inhibitors develop more frequently in patients receiving factor VIII medicines made by DNA recombinant technology than in those receiving factor VIII medicines derived from blood.

More information is available on:

Factor VIII

 
Top